A more recent version of this regulatory record is available. This version is kept only as a historical record. Please see the Record history section for link to the most recent version.

Pyrithione zinc

CAS13463-41-7
EC236-671-3

List details

Basic info

Status Opinion Adopted
Submitter Sweden
Regulatory programme
  • Existing active substance in Biocidal Products (in the meaning of Directive 98/8/EC)

Classification

Proposed harmonised classification by the dossier submitter
  • Acute Tox. 3, H301
  • Acute Tox. 2, H330
  • Eye Dam. 1, H318
  • Repr. 1B, H360D
  • STOT RE 1, H372
  • Aquatic Acute 1, H400
  • Aquatic Acute 1, M-factor=1000
  • Aquatic Chronic 1, H410
  • Aquatic Chronic 1, M-factor=10
Hazard classes open for commenting physical hazards human health hazards environmental hazards except respiratory sensitisation aspiration hazard hazardous to the ozone layer

Intention timeline

Date of intention 2016-10-12
Expected date of submission 2016-10-31
Submitted for accordance check 2016-10-26
Final submission date 2017-05-22
Start of consultation 2017-05-23
Deadline for commenting 2017-07-07
Date of opinion 2018-09-14
Legal deadline for opinion adoption 2018-11-21

Documents

CLH report
Comments received
Public consultations - received attachments
RAC opinion
Background document external link [echa.europa.eu]

Related substances

By adding any of the following substances to your watchlist, you would be monitoring this regulatory record and all possible new regulatory records related to that substance.

  • pyrithione zinc (Zinc Pyrithione)
    CAS: 13463-41-7, EC: 236-671-3

Related regulatory records

Record history

The following timeline shows when we detected changes of this regulatory record (the date might slightly differ from the date of the actual change). Additions between versions are hightlighted in green color, red color shows data removed between versions.

Feb. 4, 2019
  • Background document: https://echa.europa.eu/documents/10162/7a018644-adc1-b5ac-db26-d1c07a7a9949https://echa.europa.eu/documents/10162/c0be3353-7063-0892-961a-589b478aa855
  • Comments received: https://echa.europa.eu/documents/10162/31886937-b651-afef-cad7-8e2bff6d73ddhttps://echa.europa.eu/documents/10162/0871cef5-1841-57e1-13b0-80dfe36f7205
  • Comments received: https://echa.europa.eu/documents/10162/4ddc6396-d10b-ffcb-ce0e-c9d84261a0ebhttps://echa.europa.eu/documents/10162/def7cc6c-839a-17e0-b5ce-83214159360c
  • Comments received: https://echa.europa.eu/documents/10162/9f504468-b91e-33ac-3097-c3f7db697bd8https://echa.europa.eu/documents/10162/e832aa8b-67ce-a435-cc43-82d00c147f43
  • Comments received: https://echa.europa.eu/documents/10162/cbc296ea-cc2e-9d78-5201-3cb1cd83341f
  • Public consultations - received attachments: https://echa.europa.eu/documents/10162/39a198b3-5eb7-6354-fbfa-1555f1e93c32https://echa.europa.eu/documents/10162/1a58719d-eae8-3c92-6b50-928fbade8775
  • Public consultations - received attachments: https://echa.europa.eu/documents/10162/64a7c2a7-9459-1d29-9ae9-c444616a4751https://echa.europa.eu/documents/10162/aa5dec50-655b-a5be-08be-bae2d219de06
  • Public consultations - received attachments: https://echa.europa.eu/documents/10162/8ce82348-a7dd-510a-09a1-52cea081075bhttps://echa.europa.eu/documents/10162/d6828d48-fe79-1a78-4338-99d48672ccec
  • Public consultations - received attachments: https://echa.europa.eu/documents/10162/bb52ba51-43cf-8c24-2197-332d1b8340b4
  • RAC opinion: https://echa.europa.eu/documents/10162/203466f3-22f1-704c-0c8b-95f97b42043ahttps://echa.europa.eu/documents/10162/6405ddd0-2429-9e13-31bd-4e0752fe7430
Feb. 18, 2019
  • Regulatory programme: Existing active substance in Biocidal Products (in the meaning of Directive 98/8/EC)BPD
This version
Jan. 10, 2019
  • Background document: https://echa.europa.eu/documents/10162/e2c857c4-4087-64b6-8292-69a1c8ea720ehttps://echa.europa.eu/documents/10162/7a018644-adc1-b5ac-db26-d1c07a7a9949
  • Comments received: https://echa.europa.eu/documents/10162/31886937-b651-afef-cad7-8e2bff6d73dd
  • Comments received: https://echa.europa.eu/documents/10162/4ddc6396-d10b-ffcb-ce0e-c9d84261a0eb
  • Comments received: https://echa.europa.eu/documents/10162/e9101ae7-ba64-db65-5f10-74ffaa284d35https://echa.europa.eu/documents/10162/cbc296ea-cc2e-9d78-5201-3cb1cd83341f
  • Public consultations - received attachments: https://echa.europa.eu/documents/10162/39a198b3-5eb7-6354-fbfa-1555f1e93c32
  • Public consultations - received attachments: https://echa.europa.eu/documents/10162/64a7c2a7-9459-1d29-9ae9-c444616a4751
  • Public consultations - received attachments: https://echa.europa.eu/documents/10162/8ce82348-a7dd-510a-09a1-52cea081075b
  • RAC opinion: https://echa.europa.eu/documents/10162/0e2420f1-3186-c9b1-37d6-2bf56690bb1dhttps://echa.europa.eu/documents/10162/203466f3-22f1-704c-0c8b-95f97b42043a
Jan. 3, 2019
  • Background document: https://echa.europa.eu/documents/10162/e2c857c4-4087-64b6-8292-69a1c8ea720e
  • Comments received: https://echa.europa.eu/documents/10162/3b2a0276-871b-63a9-27e0-1d5677fc8cc2https://echa.europa.eu/documents/10162/9f504468-b91e-33ac-3097-c3f7db697bd8
  • Comments received: https://echa.europa.eu/documents/10162/c8f2fe04-7f64-ba40-bd18-e4d84af8db1ahttps://echa.europa.eu/documents/10162/e9101ae7-ba64-db65-5f10-74ffaa284d35
  • Comments received: https://echa.europa.eu/documents/10162/d6f7aec6-fbd8-e4ef-60c8-5ce4324a0a00
  • Public consultations - received attachments: https://echa.europa.eu/documents/10162/0f076026-605c-2dd7-8253-0e8658d89de6https://echa.europa.eu/documents/10162/bb52ba51-43cf-8c24-2197-332d1b8340b4
  • Public consultations - received attachments: https://echa.europa.eu/documents/10162/30163121-9c35-54c0-e26e-227ad492aeec
  • Public consultations - received attachments: https://echa.europa.eu/documents/10162/5c4e4f86-71fc-adcd-bd80-3772ee5ced6c
  • RAC opinion: https://echa.europa.eu/documents/10162/0e2420f1-3186-c9b1-37d6-2bf56690bb1d
Oct. 16, 2018
  • Date of opinion: 2018-09-14
  • Status: Opinion DevelopmentOpinion Adopted
Add the related substance to your watchlist to monitor this regulatory record.